

Appendix A: Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data




1. Was the sample frame appropriate to address the target population?
2. Were study participants sampled in an appropriate way?
3. Was the sample size adequate?
4. Were the study subjects and the setting described in detail?
5. Was the response rate adequate, and if not, was the low response rate managed appropriately?

We have omitted four questions that were not relevant for this study.


Appendix B: Risk of bias assessment

	Risk of bias domains					Overall
	D1	D2	D3	D4	D5	
Bell (2017)	+	X	+	+	+	+
Corter (2018)	+	+	+	+	?	+
Custers (2015)	+	+	+	+	+	+
Custers (2016)	+	X	+	+	X	X
Custers (2017)	+	+	+	+	X	+
Custers (2018)	?	X	+	X	?	X
Dixon (2019)	+	?	+	+	?	+
Eyrenci (2018)	+	?	+	+	?	+
Guimond (2019)	+	+	+	+	+	+
Hébert (2017)	+	+	+	+	?	+
Jakobsen (2019)	+	+	+	+	+	+
Jeppesen (2018)	+	+	+	+	X	+
Kang (2019)	?	?	?	?	?	?
Lane (2019)	+	X	+	+	?	X
Lebel (2016)	+	+	+	+	X	+
Lim (2019)	?	?	?	?	?	?
Liu (2017)	+	?	+	+	X	X
Mititelu (2016)	+	?	+	+	?	+
Ng (2019)	+	+	+	+	+	+
Otto (2018)	+	+	+	+	X	+
Russell (2019)	+	+	+	+	+	+
Shin (2017)	+	+	+	+	+	+
Simard (2009)	+	+	+	+	X	+
Simard (2010)	+	X	+	+	X	X
Sukyati (2019)	+	?	+	?	?	?
van de Wal (2016)	X	+	+	+	X	X
Van der Gucht (2017)	+	X	X	+	?	X
van Helmond (2017)	+	+	+	+	?	+
van Helmond (2020)	+	+	+	+	X	+
Vatandoust (2019)	?	?	X	?	+	?
Wijayanti (2018)	+	+	+	X	+	+
Zdenkowski (2018)	?	+	+	+	+	+

Study

Judgement
 No
 Yes
 Unclear

a)




b)

Figure 1. Risk of bias assessment of studies that provided data and did not select on level of FCR, a) shows assessment per study, b) shows a summary of all studies. Figure created using robvis (95).

Study	Risk of bias domains					Overall
	D1	D2	D3	D4	D5	
Compen (2018)	⊗	⊗	⊕	⊕	?	⊗
Dirkse (2019)	⊗	⊗	⊕	⊕	?	⊗
Fisher (2017)	⊗	⊗	⊗	⊕	?	⊗
Fisher (2019)	⊗	⊗	⊗	⊕	?	⊗
Jakobsen (2018)	⊗	⊕	⊕	⊕	⊕	⊕
Johns (2020)	⊗	⊗	⊕	⊕	⊗	⊗
Luigjes-Huizer (2019)	?	?	?	?	?	?
Maheu (2016)	⊗	⊗	⊕	⊕	⊕	⊗
Murphy (2019)	⊗	⊗	⊕	⊕	?	⊗
Savard (2013)	⊗	⊕	⊕	⊕	⊕	⊕
Savard (2018)	⊗	⊗	⊕	⊕	?	⊗
Van De Wal (2017)	⊗	⊗	⊕	⊕	⊗	⊗

Judgement
 ⊗ No
 ⊕ Yes
 ? Unclear

a)




b)

Figure 2. Risk of bias assessment of studies that provided data and selected on level of FCR, a) shows assessment per study, b) shows a summary of all studies. Figure created using robvis (95)

Study	Risk of bias domains					Overall
	D1	D2	D3	D4	D5	
Dodds (2015)	+	X	+	+	?	X
Kasparian (2016)	+	?	X	+	+	X
Merckaert (2017)	+	X	+	+	X	X
Smith (2019)	X	+	+	+	X	X
Galica (2020)	+	X	X	+	?	X
Galica (2018)	+	+	+	+	+	+
Nelson (2018)	+	+	+	+	+	+
Walburg (2019)	+	+	+	+	+	+
Costa (2016)	+	+	+	+	+	+
Batani (2019)	+	+	+	+	?	+
Leclair (2019)	+	+	+	+	?	+
Peng (2019)	+	+	+	+	?	+
Shin (2020)	+	+	+	+	?	+
Tesson (2017)	+	+	+	+	?	+
Dieng (2016)	+	X	+	+	+	+
Hong (2020)	+	?	+	+	?	+
Thewes (2012)	+	+	+	+	X	+
Van Liew (2014)	X	+	+	+	+	+
Petzel (2012)	?	?	?	?	?	?
Herman (2014)	?	?	?	?	?	?
Shun (2018)	X	?	+	?	?	?

Judgement
 X No
 + Yes
 ? Unclear

a)



b)

Figure 3. Risk of bias assessment of studies that were included in the aggregate data analysis, a) shows assessment per study, b) shows a summary of all studies. Figure created using robvis (95).

Appendix C: Main characteristics and mean FCR scores per dataset

a) Datasets that did not select participants based on their level of fear of cancer recurrence or related factors.

Author	year	n	FCR severity mean (sd)	Mean age (yrs)	Country	Language	Sex		Cancer type	Patients (n)	Survivors (n)	Mean time since cancer diagnosis (yrs)
							men (n)	women (n)				
Bell	2017	215	15.3 (6.8)	65	Australia	English	137	78	melanoma	0	215	1.3
Corter	2018	125	17.2 (7.6)	56	New Zealand	English	0	125	breast	0	125	0.4
Custers	2015	54	16.9 (7.7)	62	the Netherlands	Dutch	29	25	other	54	0	4.8
Custers	2017	460	16 (6.8)	57	the Netherlands	Dutch	0	460	breast	0	460	2.8
Custers	2016	76	11.6 (7.3)	67	the Netherlands	Dutch	40	36	colorectal	0	76	5.0
Custers	2018	150	13.2 (6.4)	68	the Netherlands	Dutch	97	53	colorectal	150	0	0.0
Dixon	2019	97	24.3 (6.8)	-	USA	English	33	64	breast, lung	0	97	-
Eyrenci	2018	217	15.3 (7.4)	51	Turkey	Turkish	43	174	multiple	0	217	4.5
Galica	<i>n.p.</i>	219	17.3 (7.9)	64	Canada	English	40	178	breast, colorectal	0	219	-
Guimond	2019	81	11.5 (5.8)	59	Canada	French	0	81	breast	81	0	0.3
Hebert	2017	38	14.2 (6.6)	69	Canada	French	0	38	endometrial	38	0	-
Jakobsen	2019	141	11.7 (6.3)	66	Denmark	Danish	100	41	colorectal	0	93	1.1
Jeppesen	2018	212	10.4 (7.1)	65	Denmark	Danish	0	212	endometrial	0	212	0.0
Kang	2019	52	12.7 (6.5)	63	Canada	English	52	0	prostate cancer	52	0	1.9
Lane	2019	554	22.8 (7)	34	Canada	English	72	482	multiple	37	301	4.9
Lebel	2016	350	13.8 (7.9)	67	Canada	English	185	165	multiple	2	295	5.9
Lim	2019	125	10.9 (6.7)	59	South Korea	Korean	80	45	colorectal	125	0	-
Liu	2017	405	13.1 (6.7)	56	Singapore	English	81	324	multiple	0	405	-
Mititelu	2016	32	16.5 (6.5)	-	Canada	English	3	29	multiple	4	13	2.2
Ng	2019	293	10.8 (7.2)	60	Hong Kong	Cantonese	76	217	breast, colorectal	0	293	0.0
Otto	2018	300	15 (7.8)	62	USA	English	0	300	breast	0	300	3.5
Russell	2019	69	16.8 (7.3)	53	Australia	English	32	37	melanoma	0	69	3.9
Shin	2017	239	15.1 (7.2)	50	South Korea	Korean	71	168	multiple	239	0	0.0
Simard	2009	1984	12.9 (6.9)	63	Canada	French	904	1080	multiple	575	1390	4.2

Simard	2010	600	12.9 (6.8)	64	Canada	French	319	281	multiple	451	149	4.7
Sukyati	2019	114	12.2 (7.9)	52	Indonesia	Indonesia	0	114	other	114	0	-
Tauber	<i>n.p.</i>	780	15.2 (7.3)	-	Denmark	Danish	0	780	breast	0	780	-
Van de Wal	2016	311	10.7 (7.1)	70	the Netherlands	Dutch	311	0	prostate	0	311	8.3
van der Gucht	2017	11	20.6 (8.1)	21	Belgium	Dutch	6	5	leukemia, lung	0	11	6.0
van Helmond	2020	454	13.9 (6.9)	58	the Netherlands	Dutch	0	454	breast	0	454	2.6
van Helmond	2017	290	18.8 (5.1)	52	the Netherlands	Dutch	39	251	-	0	290	-
Vatandoust	2019	51	12.1 (6.6)	64	Australia	English	36	15	colorectal	0	51	4.7
Wijayanti	2018	153	18.9 (5.2)	52	Indonesia	Indonesia	0	153	other	153	0	-
Zdenkowski	2018	59	15.5 (6.1)	52	Australia	English	0	59	breast	0	59	0.0

b) Datasets that did select participants based on their level of fear of cancer recurrence or related factors.

Author	year	n	FCR severity mean (sd)	Mean age (yrs)	Country	Language	Sex		Cancer type	Patients (n)	Survivors (n)	Mean time since cancer diagnosis (yrs)
							men (n)	women (n)				
Compen	2018	245	21.3 (6.5)	52	the Netherlands	Dutch	35	210	multiple	-	-	3.5
Dirkse	2020	83	21.5 (5)	51	Canada	English	14	69	multiple	0	83	2.1
Fisher	2019	27	25.6 (7.6)	51	United Kingdom	English	3	24	multiple	0	27	-
Fisher	2017	4	30.3 (4.9)	NA	United Kingdom	English	0	4	breast, endometrial	0	4	2.1
Jakobsen	2018	69	12.4 (7)	67	Denmark	Danish	39	30	colorectal	0	31	1.9
Johns	2020	91	19 (5.6)	58	USA	English	0	91	breast	0	91	5.1
Luigjes-Huizer	2019	58	17.6 (7.3)	64	the Netherlands	Dutch	21	26	multiple	0	58	6.9
Maheu	2016	136	23.1 (5.4)	56	Canada	English	0	136	multiple	0	136	2.2
Murphy	2020	114	22.4 (5.7)	53	Australia	English	13	101	multiple	-	-	4.0
Savard	2013	962	14.3 (6.9)	57	Canada	French	343	619	multiple	962	0	0.2
Savard	2018	38	21.4 (5.6)	57	Canada	French	2	36	multiple	9	16	1.1
Van de Wal	2017	88	19.3 (7.2)	59	the Netherlands	Dutch	41	47	multiple	0	88	2.6

Appendix D: Characteristics of FCR severity groups, according to different cutoffs.

For these analyses, 12 additional studies were included, that had selected participants based on the severity of their FCR. The mean FCR severity score for these additional studies was 20.7.

	< 13		13-15		16-21		≥22	
	Survivors	Patients	Survivors	Patients	Survivors	Patients	Survivors	Patients
Sex								
Men	1150 (39)	512 (40)	279 (28)	168 (34)	475 (23)	216 (27)	302 (17)	133 (23)
Women	1817 (61)	778 (60)	702 (72)	332 (66)	1581 (77)	575 (73)	1484 (83)	455 (77)
Age groups								
18-29 years	19 (1)	9 (1)	12 (1)	4 (1)	55 (3)	10 (1)	84 (5)	17 (3)
30-44 years	157 (5)	100 (8)	108 (11)	57 (11)	274 (14)	94 (12)	431 (25)	110 (19)
45-59 years	753 (26)	468 (36)	367 (38)	218 (44)	793 (40)	365 (46)	628 (37)	262 (45)
60-74 years	1505 (52)	600 (47)	384 (40)	200 (40)	733 (37)	282 (36)	481 (28)	178 (30)
≥75 years	474 (16)	113 (9)	92 (10)	20 (4)	127 (6)	36 (5)	71 (4)	20 (3)
Cancer type								
Breast cancer	1368 (47)	534 (41)	536 (57)	223 (44)	1148 (60)	385 (49)	1025 (61)	263 (45)
Colon and rectal cancer	373 (13)	235 (18)	102 (11)	56 (11)	171 (9)	112 (14)	133 (8)	61 (11)
Endometrial cancer	123 (4)	59 (5)	25 (3)	32 (6)	38 (2)	33 (4)	33 (2)	28 (5)
Leukemia & non-hodgkin lymphoma	19 (1)	1 (0)	13 (1)	1 (0)	34 (2)	3 (0)	42 (2)	9 (2)
Lung cancer	57 (2)	35 (3)	16 (2)	18 (4)	36 (2)	39 (5)	73 (4)	23 (4)
Melanoma	89 (3)	0 (0)	42 (4)	0 (0)	91 (5)	0 (0)	71 (4)	3 (0)
Prostate cancer	754 (26)	289 (22)	151 (16)	105 (21)	218 (11)	99 (13)	101 (6)	65 (11)
Thyroid cancer	4 (0)	0 (0)	8 (1)	0 (0)	9 (0)	3 (0)	25 (1)	5 (1)
Other cancer types	123 (4)	137 (11)	46 (5)	64 (13)	165 (9)	117 (15)	177 (11)	131 (22)
Time since diagnosis								
0-1 years	779 (33)	764 (69)	262 (35)	290 (67)	514 (35)	440 (65)	486 (37)	304 (60)
2-5 years	1098 (47)	246 (22)	347 (46)	107 (25)	686 (46)	160 (24)	581 (44)	142 (28)
6-10 years	328 (14)	69 (6)	100 (13)	23 (5)	203 (14)	50 (7)	174 (13)	41 (8)
>10 years	153 (6)	26 (2)	40 (5)	12 (3)	83 (6)	26 (4)	76 (6)	16 (3)

A partially imputed dataset was used: the variables FCR severity, age, cancer type and time since cancer diagnosis were not imputed, since the imputation did not converge.